ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
-11.18%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$5.48B
AUM Growth
+$5.48B
(-6.7%)
Cap. Flow
+$377M
Cap. Flow
% of AUM
6.89%
Top 10 Holdings %
Top 10 Hldgs %
68.73%
Holding
44
New
4
Increased
20
Reduced
4
Closed
1
Top Buys
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$189M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$180M |
| 3 |
argenx
ARGX
|
$91.4M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$45.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$36.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 94.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $684M | 12.48% | 6,500,000 -2,795,000 | -30% | -$294M |
|
2
United Therapeutics
UTHR
$13.8B
| $544M | 9.92% | 3,030,000 -5,000 | -0.2% | -$897K |
|
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $480M | 8.77% | 9,450,000 +894,445 | +10% | +$45.4M |
|
|
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $438M | 7.99% | 5,325,000 +250,000 | +5% | +$20.6M |
|
|
5
argenx
ARGX
$43.6B
| $396M | 7.22% | 1,255,000 +290,000 | +30% | +$91.4M |
|
|
6
SPDR S&P Biotech ETF
XBI
$5.07B
| $274M | 5% | 3,050,000 +2,000,000 | +190% | +$180M |
|
7
Ascendis Pharma
ASND
$11.8B
| $258M | 4.71% | 2,200,000 +200,000 | +10% | +$23.5M |
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $245M | 4.47% | 3,135,000 +10,000 | +0.3% | +$781K |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $234M | 4.27% | 3,035,000 +235,000 | +8% | +$18.1M |
|
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $212M | 3.88% | 1,300,000 +225,000 | +21% | +$36.7M |
|
11
Amicus Therapeutics
FOLD
$2.34B
| $194M | 3.54% | 20,500,000 +2,000,000 | +11% | +$18.9M |
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $189M | 3.46% | +1,315,000 | New | +$189M |
|
13
Xenon Pharmaceuticals
XENE
$2.98B
| $152M | 2.78% | 4,985,000 | – | – |
|
14
Iovance Biotherapeutics
IOVA
$807M
| $152M | 2.77% | 9,125,000 +450,000 | +5% | +$7.49M |
|
15
Madrigal Pharmaceuticals
MDGL
$9.76B
| $140M | 2.55% | 1,425,000 | – | – |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $122M | 2.23% | 7,250,000 | – | – |
|
17
Kura Oncology
KURA
$686M
| $77.2M | 1.41% | 4,800,000 +800,000 | +20% | +$12.9M |
|
18
Krystal Biotech
KRYS
$4.27B
| $66.9M | 1.22% | 1,005,000 +530,000 | +112% | +$35.3M |
|
19
Acadia Pharmaceuticals
ACAD
$4.38B
| $55.1M | 1.01% | 2,275,000 +75,000 | +3% | +$1.82M |
|
20
Monte Rosa Therapeutics
GLUE
$296M
| $46.4M | 0.85% | 3,311,434 | – | – |
|
21
PMV Pharmaceuticals
PMVP
$74.2M
| $45.8M | 0.84% | 2,200,000 +735,000 | +50% | +$15.3M |
|
22
Syndax Pharmaceuticals
SNDX
$1.41B
| $38.6M | 0.7% | 2,220,500 +45,500 | +2% | +$791K |
|
23
Design Therapeutics
DSGN
$315M
| $35.9M | 0.66% | 2,222,222 +586,122 | +36% | +$9.47M |
|
24
Kymera Therapeutics
KYMR
$2.95B
| $34.6M | 0.63% | 816,500 +266,500 | +48% | +$11.3M |
|
25
MannKind Corp
MNKD
$1.41B
| $32.4M | 0.59% | 8,800,000 | – | – |
|